BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Dolat Capital Report
Dr. Reddy’s Laboratories Ltd. is refocusing on -based products and ensuring the right product cost structures for the highly competitive U.S. market. Excluding Revlimid we expect a revenue compound annual growth rate of 7% in the U.S., and 11%/12% in India/Russia over FY22-24E.
Revenue growth in India would be supported by improving productivity and a focus on core therapies. Meanwhile, revenue growth in Russia would be supported by improved volume growth, in our view.
Concentration risk in the U.S. portfolio has come down largely with top 10 products contributing ~40-45% of sales.
Dr. Reddy's is focusing on timely product launches and increasing the market share of existing products. It will continue to focus on complex formulations (primarily injectable and oral solid dosage forms) and over the counter brands in the medium term, as well as 505(b)(2) generics, controlled substances, and non-substitutable generics in the longer term.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR